Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akums Drugs and PharmaceuticalsNSE:AKUMS -1.90%40 ROC (Joel Greenblatt) % is 25.74% as of Jun. 2026, which is 138% above its 10-year median of 10.82. GuruFocus rates NSE:AKUMS with a GF Score™ of 40/100. The stock has 6 warning signs investors should review. Among 980 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 65.61% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Akums Drugs and Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 25.74%.
The historical rank and industry rank for Akums Drugs and Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:AKUMS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.35 Med: 10.82 Max: 21.32
Current: 21.32
During the past 6 years, Akums Drugs and Pharmaceuticals's highest ROC (Joel Greenblatt) % was 21.32%. The lowest was -10.35%. And the median was 10.82%.
NSE:AKUMS's ROC (Joel Greenblatt) % is ranked better than 65.61% of 980
companies
in the Drug Manufacturers industry
Industry Median: 10.525
vs NSE:AKUMS: 21.32
Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals ROC (Joel Greenblatt) % Chart
NSE:AKUMS vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Akums Drugs and Pharmaceuticals ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 25.74% mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a ROC (Joel Greenblatt) % of 25.74% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is 138% above median its historical median of 10.82. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #337 out of 980 companies in the Drug Manufacturers industry, placing it in the top 34.4%.
Is Akums Drugs and Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Akums Drugs and Pharmaceuticals' current ROC (Joel Greenblatt) % of 25.74% is 138% above median its 10-year median of 10.82. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 10.53. Akums Drugs and Pharmaceuticals' value of 25.74% is 144.6% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #337 out of 980 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #337 out of 980 companies for ROC (Joel Greenblatt) %. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 10.53. Akums Drugs and Pharmaceuticals' value of 25.74% is 144.6% above this benchmark. While the company's 10-year median is 10.82 vs. the industry median of 10.53, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.53, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current ROC (Joel Greenblatt) % of 25.74% is 144.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current ROC (Joel Greenblatt) % is 25.74%, which is 138% above median its own 10-year median of 10.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current ROC (Joel Greenblatt) % of 25.74%. The current ROC (Joel Greenblatt) % is 25.74%, which is 138% above median its 10-year median of 10.82 and 144.6% above the Drug Manufacturers industry median of 10.53. Akums Drugs and Pharmaceuticals' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current ROC (Joel Greenblatt) % is 25.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
40GF Score
Get the complete analysis for NSE:AKUMS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
